{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:49:49Z","timestamp":1789609789314,"version":"build-2803163510"},"reference-count":144,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Obesity is a chronic, highly prevalent disease affecting nearly one-third of the global population and represents a major independent risk factor for heart failure (HF), particularly heart failure with preserved ejection fraction (HFpEF). Excess adiposity\u2014especially visceral and epicardial adipose tissue (EAT)\u2014acts as an active endocrine and immune organ, promoting chronic low-grade inflammation, oxidative stress, endothelial dysfunction, and adverse myocardial remodeling. Expanded EAT exerts both paracrine inflammatory effects and mechanical constraint on the myocardium, contributing to diastolic dysfunction, microvascular impairment, atrial arrhythmogenesis, and elevated filling pressures despite preserved systolic function. Evidence demonstrates a dose\u2013response relationship between increasing body mass index and incident HF. Clinically, obesity-related HFpEF is characterized by concentric left ventricular hypertrophy, impaired relaxation, increased plasma volume, reduced exercise tolerance, and relatively low natriuretic peptide levels, complicating diagnosis. HF management includes traditional treatment with diuretics, renin-angiotensin system inhibitors, \u03b2-blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitors. These agents widely remain foundational as they primarily target hemodynamic and neurohormonal pathways in HF. In contrast, sodium\u2013glucose cotransporter 2 inhibitors consistently reduce HF hospitalizations across the ejection fraction spectrum, while glucagon-like peptide-1 receptor agonists and dual incretin therapies (e.g., tirzepatide) promote substantial weight loss, improve symptoms, and demonstrate promising anti-remodeling effects in obesity-related HFpEF. Recognizing obesity-driven HF as a distinct cardiometabolic entity supports an integrated therapeutic strategy combining structured weight reduction with guideline-directed HF polypharmacotherapy to address both hemodynamic burden and upstream adiposity-related mechanisms.<\/jats:p>","DOI":"10.3390\/jcdd13040153","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:40:52Z","timestamp":1774878052000},"page":"153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obesity and Heart Failure: Introducing the Theme"],"prefix":"10.3390","volume":"13","author":[{"given":"Francesco","family":"Monitillo","sequence":"first","affiliation":[{"name":"Cardiology University Unit, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Basile","sequence":"additional","affiliation":[{"name":"Unit of Cardiology, San Pio Hospital, Via del Mercato, 74011 Castellaneta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6521-8578","authenticated-orcid":false,"given":"Giuseppe","family":"Lisco","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari \u201cAldo Moro\u201d, Piazza Giulio Cesare 11, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100375","DOI":"10.1016\/j.metop.2025.100375","article-title":"Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions","volume":"27","author":"Ahmed","year":"2025","journal-title":"Metabol. Open"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"M\u0142ynarska, E., Bojdo, K., Frankenstein, H., Krawiranda, K., Kustosik, N., Lisi\u0144ska, W., Rysz, J., and Franczyk, B. (2025). Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262010096"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-025-02612-z","article-title":"Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity","volume":"24","author":"Chin","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-3-319-48382-5_15","article-title":"Endothelial Dysfunction in Obesity","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kajikawa, M., and Higashi, Y. (2022). Obesity and Endothelial Function. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071745"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2019.04.019","article-title":"Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis","volume":"7","author":"Reddy","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.ijo.0803726","article-title":"Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease","volume":"32","author":"Cheng","year":"2008","journal-title":"Int. J. Obes."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jacc.2005.10.062","article-title":"Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function","volume":"47","author":"Schindler","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101841","DOI":"10.1016\/j.cpcardiol.2023.101841","article-title":"Epicardial Adipose Tissue in Myocardial Disease: From Physiology to Heart Failure Phenotypes","volume":"48","author":"Antonopoulos","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"36598","DOI":"10.31083\/RCM36598","article-title":"Recent Advances in Inflammation-Associated Epicardial Adipose Tissue for Atrial Fibrillation Patients","volume":"26","author":"Li","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: An ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/cvr\/cvab368","article-title":"Obesity increases heart failure incidence and mortality: Observational and Mendelian randomization studies totalling over 1 million individuals","volume":"118","author":"Benn","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e029062","DOI":"10.1161\/JAHA.122.029062","article-title":"Body Composition and Risk of Incident Heart Failure in 1 Million Adults: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies","volume":"12","author":"Oguntade","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.23736\/S2724-5683.23.06367-6","article-title":"Impact of Body Mass Index on outcomes in hospitalized heart failure patients with reduced versus preserved ejection fraction: A 1,699,494-individual analysis from the United States National Inpatient Sample","volume":"72","author":"Ansari","year":"2024","journal-title":"Minerva Cardiol. Angiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s43856-023-00353-2","article-title":"Waist-hip ratio is superior to BMI in predicting liver-related outcomes and synergizes with harmful alcohol use","volume":"3","author":"Salomaa","year":"2023","journal-title":"Commun. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41366-025-01895-2","article-title":"Epidemiological associations between obesity, metabolism and disease risk: Are body mass index and waist-hip ratio all you need?","volume":"49","author":"Zhao","year":"2025","journal-title":"Int. J. Obes."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes. Facts"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.17925\/HI.2023.17.2.4","article-title":"Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity","volume":"17","author":"Binu","year":"2023","journal-title":"Heart Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S0029665124007559","article-title":"Exploring the association between sarcopenic obesity and cardiovascular risk: A summary of findings from longitudinal studies and potential mechanisms","volume":"84","author":"Guan","year":"2025","journal-title":"Proc. Nutr. Soc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2008.02.014","article-title":"Body mass index and mortality in heart failure: A meta-analysis","volume":"156","author":"Oreopoulos","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"El-Khoury, R., Mahfoud, Z., Dargham, S., Pal, M.A., Jayyousi, A., Al Suwaidi, J., and Abi Khalil, C. (2025). Obesity Is Associated with a Lower Risk of Mortality and Readmission in Heart Failure Patients with Diabetes. Biomedicines, 13.","DOI":"10.3390\/biomedicines13123086"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/heartjnl-2023-322459","article-title":"Body mass index and survival in people with heart failure","volume":"109","author":"Jones","year":"2023","journal-title":"Heart"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MEJ.0000000000000354","article-title":"OBESICA study: Relationship between BMI and acute heart failure outcome","volume":"24","author":"Rizzi","year":"2017","journal-title":"Eur. J. Emerg. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101553","DOI":"10.1016\/j.jacadv.2024.101553","article-title":"Skeletal Muscle Mass and Mortality in Heart Failure: Mediation Role of Systemic Immune-Inflammatory Index","volume":"4","author":"Cai","year":"2025","journal-title":"JACC Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/07853890.2016.1197415","article-title":"Complex relationship of obesity and obesity paradox in heart failure-higher risk of developing heart failure and better outcomes in established heart failure","volume":"48","author":"Alagiakrishnan","year":"2016","journal-title":"Ann. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1002\/ehf2.13021","article-title":"Loss of skeletal muscle mass predicts cardiac death in heart failure with a preserved ejection fraction but not heart failure with a reduced ejection fraction","volume":"7","author":"Matsumura","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s11886-023-01975-7","article-title":"Obesity, Cardiorespiratory Fitness, and Cardiovascular Disease","volume":"25","author":"Haidar","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"BSR20182278","DOI":"10.1042\/BSR20182278","article-title":"Association between epicardial adipose tissue and adverse outcomes in coronary heart disease patients with percutaneous coronary intervention","volume":"39","author":"Lu","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research Priorities for Heart Failure with Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s10741-025-10540-z","article-title":"Time to screen: Rationale and roadmap for HFpEF screening in individuals with obesity","volume":"30","author":"Achten","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCULATIONAHA.118.035711","article-title":"H2FPEF Score: At Last, a Properly Validated Diagnostic Algorithm for Heart Failure with Preserved Ejection Fraction","volume":"138","author":"Paulus","year":"2018","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jchf.2020.03.013","article-title":"Application of Diagnostic Algorithms for Heart Failure with Preserved Ejection Fraction to the Community","volume":"8","author":"Selvaraj","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ejhf.2019","article-title":"The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction","volume":"23","author":"Henkens","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hlc.2021.06.525","article-title":"The Effect of Obesity on Echocardiographic Image Quality","volume":"31","author":"Ellenberger","year":"2022","journal-title":"Heart Lung Circ."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e011366","DOI":"10.1161\/CIRCHEARTFAILURE.123.011366","article-title":"Uncovering Unrecognized Heart Failure with Preserved Ejection Fraction Among Individuals with Obesity and Dyspnea","volume":"17","author":"Kosyakovsky","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic Treatment in Heart Failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17308","DOI":"10.1074\/jbc.M112.356014","article-title":"Loop diuretic and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl cotransporter (NKCC1)","volume":"287","author":"Somasekharan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"R134","DOI":"10.1186\/cc13952","article-title":"Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: A prospective randomized trial","volume":"18","author":"Palazzuoli","year":"2014","journal-title":"Crit. Care"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100465","DOI":"10.1016\/j.xkme.2022.100465","article-title":"Renin-Angiotensin-Aldosterone System Activation and Diuretic Response in Ambulatory Patients with Heart Failure","volume":"4","author":"Amatruda","year":"2022","journal-title":"Kidney Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2025.04.029","article-title":"Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction","volume":"289","author":"Benson","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cardfail.2012.09.005","article-title":"Obesity and the response to intensified diuretic treatment in decompensated heart failure: A DOSE trial substudy","volume":"18","author":"Gupta","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized with Heart Failure: The TRANSFORM-HF Randomized Clinical Trial","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in Acute Decompensated Heart Failure with Volume Overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41586-023-05718-0","article-title":"Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter","volume":"614","author":"Fan","year":"2023","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/heartjnl-2021-319643","article-title":"Efficacy and safety of diuretics in heart failure with preserved ejection fraction: A scoping review","volume":"108","author":"Singh","year":"2022","journal-title":"Heart"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/ejhf.2988","article-title":"Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: A post-hoc analysis of the CLOROTIC trial","volume":"25","author":"Casado","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tem.2006.07.001","article-title":"Adrenergic receptor polymorphisms and autonomic nervous system function in human obesity","volume":"17","author":"Yasuda","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/heartjnl-2019-315568","article-title":"Assessment and management of cardiovascular disease in the intensive care unit","volume":"108","author":"Cook","year":"2022","journal-title":"Heart"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jjcc.2013.02.018","article-title":"Heart rate: A global target for cardiovascular disease and therapy along the cardiovascular disease continuum","volume":"62","author":"Custodis","year":"2013","journal-title":"J. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e019240","DOI":"10.1161\/JAHA.120.019240","article-title":"Beta-Blocker Use Is Associated with Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy","volume":"10","author":"Enzan","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102376","DOI":"10.1016\/j.cpcardiol.2024.102376","article-title":"Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis","volume":"49","author":"Kaddoura","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2018.03.089","article-title":"Effect of beta-adrenergic blockade on weight changes in patients with chronic heart failure","volume":"264","author":"Sze","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","article-title":"Obesity-Related Heart Failure with a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2","volume":"6","author":"Packer","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Netala, V.R., Teertam, S.K., Li, H., and Zhang, Z. (2024). A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells, 13.","DOI":"10.3390\/cells13171471"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/VHRM.S1899","article-title":"Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention","volume":"4","author":"Cuspidi","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10741-012-9329-8","article-title":"Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction","volume":"18","author":"Agarwal","year":"2013","journal-title":"Heart Fail. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Turgeon, R.D., Kolber, M.R., Loewen, P., Ellis, U., and McCormack, J.P. (2019). Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212907"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2B","DOI":"10.1016\/0002-9149(85)90607-1","article-title":"Basic cellular mechanisms of action of the calcium-channel blockers","volume":"55","author":"Katz","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157340206776877370","article-title":"New Generation Calcium Channel Blockers in Hypertensive Treatment","volume":"2","author":"Ozawa","year":"2006","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ibneur.2025.01.002","article-title":"Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies","volume":"18","author":"Hatamian","year":"2025","journal-title":"IBRO Neurosci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1753944716642677","article-title":"Cardiac remodelling and RAS inhibition","volume":"10","author":"Ferrario","year":"2016","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_71","first-page":"101515","article-title":"Effects of calcium channel blockers in patients with heart failure with preserved and mildly reduced ejection fraction: A systematic review and meta-analysis","volume":"55","author":"Fukuta","year":"2024","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjmed.2021.06.013","article-title":"Trends in Calcium Channel Blocker Use in Patients with Heart Failure with Reduced Ejection Fraction and Comorbid Atrial Fibrillation","volume":"134","author":"Cholack","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_73","first-page":"e895","article-title":"ACC\/AHA Joint Committee Members. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics","volume":"13","author":"Epstein","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1055\/s-2005-870240","article-title":"Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes","volume":"37","author":"Kraus","year":"2005","journal-title":"Horm. Metab. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e290224227534","DOI":"10.2174\/011573403X281390240219063817","article-title":"Aldosterone Effect on Cardiac Structure and Function","volume":"20","author":"Abdu","year":"2024","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1161\/CIRCULATIONAHA.111.067918","article-title":"Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling","volume":"124","author":"Leopold","year":"2011","journal-title":"Circulation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/heartjnl-2012-303329","article-title":"Fibrosis and cardiac function in obesity: A randomised controlled trial of aldosterone blockade","volume":"99","author":"Kosmala","year":"2013","journal-title":"Heart"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: An individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Habib, E., Ibrahim, R., Pham, H.N., Abdelnabi, M., Kanaan, C., Eldeib, A., Augusto, S.N., Ayoub, C., Tang, W.H.W., and Arsanjani, R. (2025). Finerenone Versus Spironolactone for Heart Failure with Preserved Ejection Fraction. Cardiovasc. Drugs Ther.","DOI":"10.1007\/s10557-025-07822-x"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","article-title":"Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus","volume":"15","author":"Jin","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial","volume":"85","author":"Vaduganathan","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The Adipokine Hypothesis of Heart Failure with a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ijo.2010.227","article-title":"Neprilysin, obesity and the metabolic syndrome","volume":"35","author":"Standeven","year":"2011","journal-title":"Int. J. Obes."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jacbts.2020.07.006","article-title":"Differential Effects of Sacubitril\/Valsartan on Diastolic Function in Mice with Obesity-Related Metabolic Heart Disease","volume":"5","author":"Croteau","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","article-title":"Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: Revisiting the obesity paradox","volume":"44","author":"Butt","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.hlc.2023.11.022","article-title":"The Effect of Weight Loss Through Lifestyle Interventions in Patients with Heart Failure with Preserved Ejection Fraction\u2014A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"33","author":"Lee","year":"2024","journal-title":"Heart Lung Circ."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/eurjpc\/zwad166","article-title":"Fluid balance in heart failure","volume":"30","author":"Cosentino","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2014A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.trsl.2014.05.001","article-title":"Obesity, metabolic dysfunction, and cardiac fibrosis: Pathophysiological pathways, molecular mechanisms, and therapeutic opportunities","volume":"164","author":"Cavalera","year":"2014","journal-title":"Transl. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1111\/dom.70164","article-title":"Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes","volume":"27","author":"Alghamdi","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12933-023-02035-8","article-title":"Impact of SGLT2 inhibitors on patient outcomes: A network meta-analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kongmalai, T., Hadnorntun, P., Leelahavarong, P., Kongmalai, P., Srinonprasert, V., Chirakarnjanakorn, S., Chaikledkaew, U., McKay, G., Attia, J., and Thakkinstian, A. (2023). Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: A systematic review and network meta-analysis of randomized controlled trials. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1216160"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: A meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure with Preserved Ejection Fraction: The CAMEO-DAPA Trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/ejhf.2308","article-title":"Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index","volume":"23","author":"Adamson","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: The CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jamacardio.2022.2924","article-title":"Association of Empagliflozin Treatment with Albuminuria Levels in Patients with Heart Failure: A Secondary Analysis of EMPEROR-Pooled","volume":"7","author":"Ferreira","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-8587(16)00049-8","article-title":"Heart failure event definitions in drug trials in patients with type 2 diabetes","volume":"4","author":"Sharma","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/dom.16050","article-title":"Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial","volume":"27","author":"Cosentino","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e249305","DOI":"10.1001\/jamanetworkopen.2024.9305","article-title":"Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients with Heart Failure","volume":"7","author":"Modzelewski","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1111\/dom.70102","article-title":"Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomised controlled trials","volume":"27","author":"Talavera","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e70043","DOI":"10.1111\/obr.70043","article-title":"GLP-1 Receptor Agonists for the Prevention of New-Onset Heart Failure: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials","volume":"27","author":"Neves","year":"2025","journal-title":"Obes. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Jia, A., Yang, M., Wang, T., Hua, Y., and Lu, H. (2025). Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: A meta-analysis. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1633114"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s40265-023-01932-2","article-title":"Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"83","author":"Zhao","year":"2023","journal-title":"Drugs"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"102660","DOI":"10.1016\/j.jchf.2025.102660","article-title":"Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights from the STEP-HFpEF Program","volume":"13","author":"Borlaug","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of Semaglutide on Cardiac Structure and Function in Patients with Obesity-Related Heart Failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program","volume":"84","author":"Verma","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"ehaf784.1248","DOI":"10.1093\/eurheartj\/ehaf784.1248","article-title":"GLP-1 receptor agonists for obesity-related heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials","volume":"46","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaf014","article-title":"Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: A cohort study","volume":"11","author":"Chen","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1111\/dom.70143","article-title":"Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial","volume":"27","author":"Hankosky","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients with Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial","volume":"85","author":"Packer","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients with Heart Failure and a Preserved Ejection Fraction with Obesity: A Prespecified Stratification-Based Analysis","volume":"86","author":"Packer","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, Preserved Ejection Fraction, and Obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10741-023-10338-x","article-title":"Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: Evidence from clinical trials","volume":"29","author":"Meifang","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure: A Report of the American College of Cardiology","volume":"86","author":"Kittleson","year":"2025","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/4\/153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:12:24Z","timestamp":1774948344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/4\/153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":144,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcdd13040153"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13040153","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}